Gerd Dr. Möller

Accomplished Medical leader in biopharmaceuticals and healthcare with a successful track record in national and international executive roles. Demonstrated adaptability through international living and work experiences in multiple countries and cultures. Certified emergency physician with a doctoral thesis on myocardial infarction, holding qualifications in pharmaceutical medicine and health
economics. Skilled in developing strategies and solutions to optimise Medical Affairs with strong strategic thinking and problem-solving abilities. Adept at leading diverse departments, including Medical Affairs, Medical Information, Clinical Applications, Pharmacovigilance and Regulatory Affairs.
 

CORE COMPETENCIES
Biopharmaceutical Leadership | Building and Retaining Teams I Strategy Development | Pharmaceutical Medicine | Medical Affairs
Optimisation | Product Innovation | Drug Launch Excellence | Product Life-Cycle Management | Insight Generation I Market Access |
Optimizing Pricing and Reimbursement Negotiations I Final ABPI Medical Signatory (certifier) experience I AMNOG procedure I Early
Access Programs I Investigator-Initiated Studies I KOL Engagement I Medical Budget Management | Value Communication |
Multichannel Medical Communication I Market and Stakeholder Engagement I Medical Information I Clinical Development | Business
Development | Real World Evidence Generation | Specialty & Rare Diseases I Cardiovascular I Bone I Nephrology I Neuroscience I
Respiratory I Kidney Transplant I Ophthalmology I Autoimmune Diseases I Oncology I Metabolic Diseases I Vaccinces I Regenerative
Medicine I Orthopaedic & Trauma Surgery I Bone Pathology

CAREER HIGHLIGHTS
􀂃 Launched multiple successful drugs in diverse disease areas, including cardiovascular health, X-linked hypophosphatemia (XLH),
anticoagulation, oncology, vaccines, kidney transplant, myasthenia gravis, uveal melanoma, and osteoporosis, demonstrating a
versatile and impactful pharmaceutical career.
􀂃 Honoured as a “Top Leader in the Life Sciences Industry” in year 2023 by journal “Life Sciences Review Magazine”.
􀂃Won German journal "Pharmazeutische Zeitung" Innovation Award in 2021 for Bempedoic acid (Nilemdo®).
􀂃 Introduced Bempedoic acid (Nilemdo®) as a treatment, earning a 2020 German Prix Galien Primary Care Product Award nod.
􀂃 Shortlisted Crysvita® for the UK Prix Galien 2018 and the German Prix Galien 2018 Orphan Product Award.
􀂃 Directed a team of 55+ full-time employees, while maintaining oversight of budgets reaching up to GBP 6.7M.
􀂃 Integrated medical and scientific insights in EU strategy, planning, and interventional and non-interventional studies execution.
􀂃 Led data analysis workshops and initiated cross-functional research projects for product value in reimbursement and claims.
􀂃 Seven years of clinical training in Orthopedic & Trauma Surgery and Bone Pathology at top university hospitals in Germany & the UK.
􀂃 Established a versatile medical expertise in multiple therapeutic areas, including cardio-vascular, osteoporosis, rickets, osteomalacia,
nephrology, respiratory, ophthalmology, neurology, autoimmune diseases, oncology, metabolic diseases, vaccinces and rare and very
rare diseases.

Medical Doctor with PhD, emergency physician, orthopaedic surgeon, health economist